角膜因其特有的内部有序排列结构具有高度透明性，是眼前部重要的屈光间质，又因其缺乏血液供应，角膜疾病恢复周期较长、病情易反复出现，严重影响患者的视力和日常生活。基质金属蛋白酶(matrix metalloproteinase, MMP)通过参与组织蛋白降解重塑、血管生成、炎症免疫反应等，在肺纤维化、动脉粥样硬化等众多疾病中具有重要作用，其中MMP-2(明胶酶A)在眼部相关疾病中的作用也逐渐受到关注。单纯疱疹病毒性角膜炎具有高度致盲性，反复发作会导致角膜失去透明性，角膜混浊逐渐加重，最终导致失明。研究者通过对MMP-2在HSK、角膜溃疡中的病理作用机制进行分析研究，发现MMP-2的特异性抑制药物在角膜炎中具有一定的临床应用前景，未来或可从本文的研究角度出发，适当增加相关的药物治疗研发，解决目前治疗的局限性，以期为角膜疾病患者带来新的有效治疗方案。

The cornea has a high degree of transparency due to its unique internal orderly arrangement structure, and as a major refractive media in the anterior eye. However, due to its lack of blood supply, the recovery period of corneal diseases is long and the condition is prone to recurrence, corneal diseases seriously affecting the patient's vision and daily life. Matrix Metalloproteinases play an important role in many diseases, such as pulmonary fibrosis and atherosclerosis, by participating in tissue protein degradation and remodelling, angiogenesis, inflammatory immune response, etc. Among them, the role of MMP-2 in ocular diseases has also been gradually explored and studied. Herpes simplex virus keratitis is highly blinding, and repeated attacks can cause the cornea to lose transparency, gradually worsen corneal opacity, ultimately resulting in blindness. By analysing the mechanism of MMP-2 in herpesvirus keratitis and corneal ulcers, researchers were found that specific inhibitions of MMP-2 have certain clinical application prospects in keratitis. In the future, from the perspective of this study, it may be appropriate to increase the research and development of related drug treatments, solve the limitations of current treatments, and bring new effective treatment options for corneal disease patients.

单纯疱疹病毒基质型角膜炎是引起角膜盲的主要原因之一，目前以局部使用糖皮质激素联合口服抗病毒药物治疗为主。传统治疗存在生物利用度低、药物不良反应等缺点，因此亟需寻找替代药物、开发新剂型。环孢素A和他克莫司等免疫抑制剂疗效明显、不良反应少，可能是糖皮质激素的潜在替代品。α干扰素联合阿昔洛韦可缩短病程，而单独使用效果有限。基质再生剂具有新的抗病毒机制，值得进一步研究。此外，纳米载体递送系统，如脂质体、纳米胶束、立方液晶纳米粒，由于能够增强药物角膜穿透性和延长药物释放，在治疗基质型单纯疱疹性角膜炎方面具有巨大潜力。

Herpes simplex virus stromal keratitis is one of the leading causes of corneal blindness. A topical corticosteroid

agent in conjunction with an oral antiviral agent is the preferred treatment, which has the disadvantages of low bioavailability and drug side effects. Therefore, there is an urgent need to find alternative drugs and develop new dosage forms. Immunosuppressants such as cyclosporine A and tacrolimus have obvious curative effects and few side effects, and may be potential substitutes for glucocorticoids. Interferon-α combined with acyclovir can shorten the course of disease, but the effect is not obvious when used alone. Matrix regenerating agents have new antiviral mechanisms and deserve further study. In addition, nanocarriers delivery systems, such as liposomes, nanomicelles and cubosomes, have great potential in the treatment of herpes simplex virus stromal keratitis due to their ability to enhance drug corneal penetration and prolong drug release.